SCHEMBL1618240

SCHEMBL1618240

CC(=O)NS(=O)(=O)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.48
CA1 P00915 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 1/20 0.47
EPHX1 P07099 1/20 0.34
DHFR P00374 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PTPN11 Q06124 1/20 0.32
F2 P00734 2/20 0.32
PRSS1 P07477 2/20 0.32
PRSS2 P07478 2/20 0.32
PRSS3 P35030 2/20 0.32
KDM4E B2RXH2 1/20 0.32
PTGS1 P23219 1/20 0.32
MMP12 P39900 1/20 0.32
POLB P06746 1/20 0.32
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL27839155 0.91 MAPK1 (0.42) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL6856461 0.84 MAPK1 (0.38) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL13271935 0.81 MAPK1 (0.39) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL13271977 0.78 MAPK1 (0.37) CA2CA1SMN1; SMN2MAPK1
SCHEMBL25708327 0.78 CA2 (0.52) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL10789031 0.78 CA2 (0.52) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL14477969 0.77 CA1 (0.46) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL17853345 0.77 CA1 (0.41) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL19810864 0.76 CA1 (0.50) CA2CA1SMN1; SMN2MAPK1EPHX1
SCHEMBL9944590 0.76 SMN1; SMN2 (0.34) CA2SMN1; SMN2MAPK1EPHX1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250343260-A1 SOLID ELECTROLYTES IMEC VZW (BE) 2025-11-06 US disclosed
EP-4280335-B1 SOLID ELECTROLYTES IMEC VZW (BE) 2025-05-07 EP disclosed
US-12018000-B2 Lithium salts of cyano-substituted imidazole for lithium ion batteries HYDRO-QUéBEC (CA) 2024-06-25 US disclosed
US-12018000-B2 Lithium salts of cyano-substituted imidazole for lithium ion batteries HYDRO-QUéBEC (CA) 2024-06-25 US disclosed
CN-109321157-B Adhesive composition for optical film, adhesive layer for optical film, optical film with adhesive layer, and image display device 日东电工株式会社 2024-03-12 CN disclosed
WO-2023222511-A1 SOLID ELECTROLYTES IMEC VZW (BE) 2023-11-23 WO disclosed
EP-4280335-A1 SOLID ELECTROLYTES Imec VZW (BE) 2023-11-22 EP disclosed
US-20230276792-A1 SELECTIVE HERBICIDES BASED ON SUBSTITUTED ISOXAZOLIN CARBOXAMIDES AND CLOQUINTOCET-MEXYL BAYER AKTIENGESELLSCHAFT (DE) 2023-09-07 US disclosed
US-11738004-B2 Indomethacin analogs for the treatment of castrate-resistant prostate cancer VANDERBILT UNIVERSITY (US) 2023-08-29 US disclosed
US-20230161252-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
EP-1479676-A1 Benzimidazole-derivatives as factor xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
EP-1479675-A1 Indazole-derivatives as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
EP-1479679-A1 Triazole-derivatives as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
EP-1479680-A1 Azaindole derivatives as Factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
WO-2004056815-A1 PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-07-08 WO disclosed
WO-2004050636-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-17 WO disclosed
EP-1414088-A1 NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL, AND METHOD FOR OPTIMIZING NEGATIVE ELECTRODE USING ELECTROLYTE CONTAINING ONIUM SALT Tokuyama Corporation (JP) 2004-04-28 EP disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 WO disclosed
US-20030096163-A1 Non aqueous electrolyte secondary battery SANYO ELECTRIC CO., LTD. (JP) 2003-05-22 US disclosed
EP-0399291-A2 Substituted (Quinoline-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides , process for their preparation and their use in medicines BAYER AG (DE) 1990-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11738004-B2 Indomethacin analogs for the treatment of castrate-resistant prostate cancer AKR1C3, AKR1C4, AKR1C1 CA2 569/4885CA1 244/4885SMN1; SMN2 4767/4885
US-20230276792-A1 SELECTIVE HERBICIDES BASED ON SUBSTITUTED ISOXAZOLIN CARBOXAMIDES AND CLOQUINTOCET-MEXYL AADAC, ABAT, ABCG2 CA2 285/4885CA1 2513/4885SMN1; SMN2 4291/4885
US-12018000-B2 Lithium salts of cyano-substituted imidazole for lithium ion batteries HCN2, HCN3, HLCS CA2 49/4885CA1 292/4885SMN1; SMN2 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.